AbbVie 2013 Annual Report Download - page 151

Download and view the complete annual report

Please find page 151 of the 2013 AbbVie annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 176

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176

Summary Compensation Table
This section contains compensation information for AbbVie’s named executive officers for the
fiscal year ended December 31, 2013. Because each of AbbVie’s named executive officers was employed
by Abbott Laboratories (‘‘Abbott’’) prior to AbbVie’s separation from Abbott on January 1, 2013, the
information provided for periods prior to January 1, 2013 reflects compensation earned at Abbott and
the design and objectives of Abbott executive compensation programs. All references in the following
tables to stock options, restricted stock and restricted stock units granted prior to January 1, 2013
relate to awards granted by Abbott in respect of Abbott common shares. Pursuant to the Employee
Matters Agreement dated December 31, 2012 by and between AbbVie and Abbott, these equity
awards, other than performance-based restricted shares granted to named executive officers on
December 1, 2012, were converted into awards in respect of AbbVie common stock and awards in
respect of Abbott common shares reflecting the respective post-Separation values of AbbVie and
Abbott. The performance-based restricted shares granted to named executive officers on December 1,
2012 were converted entirely into performance-based awards of restricted AbbVie common stock.
The following table summarizes compensation awarded to, earned by, or paid to AbbVie’s named
executive officers in connection with their service to AbbVie during 2013 and, as applicable, to Abbott
before 2013. Mr. Richmond was not a named executive officer before 2013. The section of this proxy
statement captioned ‘‘Compensation Discussion and Analysis—How Executive Pay Decisions Are
Made’’ describes in greater detail the information reported in this table.
Change in
Pension
Value and
Non-Equity Non-qualified
Incentive Deferred
Stock Option Plan Compensation All Other
Salary Bonus Awards Awards Compensation Earnings Compensation Total
Name and Principal Position Year ($) ($) ($)(1) ($)(2)(3) ($)(4) ($)(5) ($)(6) ($)
Richard A. Gonzalez ....... 2013 $1,500,000 $0 $9,246,994 $3,616,574 $3,300,000 $41,612 $471,614 $18,176,794
Chairman of the Board and 2012 863,942 0 3,341,844 729,640 2,500,000 64,503 449,288 7,949,217
Chief Executive Officer 2011 825,000 0 1,826,132 343,273 1,230,000 882,988 445,446 5,552,839
Laura J. Schumacher ...... 2013 900,000 0 2,555,732 1,035,626 1,290,000 944,548 270,392 6,996,298
Executive Vice President, 2012 831,682 1,100,000(7) 4,486,690 576,809 1,270,000 1,771,306 156,261 10,192,748
Business Development, 2011 827,500 0 1,905,327 358,225 1,180,000 1,138,123 158,318 5,567,493
External Affairs and General
Counsel
William J. Chase ......... 2013 790,000 0 2,034,396 795,752 1,100,000 315,787 76,788 5,112,723
Executive Vice President, 2012 398,942 500,000(7) 2,113,216 162,079 500,000 498,991 45,689 4,218,917
Chief Financial Officer 2011 375,000 0 628,898 118,370 330,000 316,489 50,734 1,819,491
Carlos Alban ........... 2013 710,000 0 2,034,396 795,752 1,030,000 416,924 148,097 5,135,169
Executive Vice President, 2012 615,769 300,000(7) 2,702,141 331,473 675,000 1,801,009 104,278 6,529,670
Commercial Operations 2011 602,471 0 1,514,013 285,334 610,000 774,355 106,162 3,892,335
Timothy J. Richmond ...... 2013 545,000 0 1,528,847 597,965 525,000 53,866 51,841 3,302,519
Senior Vice President,
Human Resources
(1) In accordance with Securities and Exchange Commission rules, the amounts in this column
represent the aggregate grant date fair value of the awards in accordance with Financial
Accounting Standards Board ASC Topic 718. AbbVie determines the grant date fair value of stock
awards by multiplying the number of shares granted by the average of the high and low market
prices of one share of AbbVie common stock on the award grant date.
(2) In accordance with Securities and Exchange Commission rules, the amounts in this column
represent the aggregate grant date fair value of the awards in accordance with Financial
Accounting Standards Board ASC Topic 718. These amounts include the grant date fair values of
$28,837 and $7,135 attributable to AbbVie and Abbott replacement stock options issued in 2013 to
28